Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response

PURPOSE: The current standard chemotherapy for advanced biliary tract cancer (BTC) has limited benefit, and novel therapies need to be investigated. MATERIALS AND METHODS: In this prospective cohort study, programmed death ligand-1 (PD-L1)–positive BTC patients who progressed on first-line gemcitabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Junho, Jeong, Jae Ho, Hwang, Hee-Sang, Lee, Sang Soo, Park, Do Hyun, Oh, Dong Wook, Song, Tae Jun, Kim, Ki-Hun, Hwang, Shin, Hwang, Dae Wook, Kim, Song Cheol, Park, Jin-hong, Hong, Seung-Mo, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Yoo, Changhoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176957/
https://www.ncbi.nlm.nih.gov/pubmed/32019287
http://dx.doi.org/10.4143/crt.2019.493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176957/
https://www.ncbi.nlm.nih.gov/pubmed/32019287
http://dx.doi.org/10.4143/crt.2019.493

Ejemplares similares